Literature DB >> 124520

Sensitivity tests of tumors to cytostatic agents. II. Investigation on human tumors.

J Mattern, M Kaufmann, H Hinderer, K Wayss, M Volm.   

Abstract

Certain substances which influenced nucleic acid metabolism were found to have about the same cytostatic activity on human cells when measured in tissue culture experiments (cell numbers) or in short-term cultures (3-H-uridine incorporation in cell suspensions). By treatment with a dose of cytostatics corresponding to 10 times therapeutic dose, chemosensitive tumors can be distinguished from non-responsive tumors. By using this in vitro test system to investigate the sensitivities of 100 human tumors, it is shown that 28 of these tumors were responsive to adriamycin, daunomycin and Actinomycin D. Good agreement was observed between these in vitro results and the literature data on clinical therapy using these particular substances.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 124520     DOI: 10.1007/bf00282976

Source DB:  PubMed          Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol        ISSN: 0084-5353


  12 in total

1.  [THE CULTIVATION OF HUMAN CANCER TISSUE IN TISSUE CULTURE AND DETERMINATION OF ITS SENSITIVITY TOWARDS NEW CYTOSTATICS].

Authors:  H LIMBURG; M KRAHE
Journal:  Dtsch Med Wochenschr       Date:  1964-10-09       Impact factor: 0.628

2.  Comparative chemotherapy studies on primary short-term cultures of human normal, benign, and malignant tumor tissues--a five-year study.

Authors:  J P COBB; D G WALKER; J C WRIGHT
Journal:  Cancer Res       Date:  1961-06       Impact factor: 12.701

3.  Chemotherapy of ovarian cancer. New approaches to treatment.

Authors:  J P Smith; F Rutledge; J T Wharton
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

4.  Results of a clinical trial with intermittent doses of adriamycin in lung cancer.

Authors:  Y Kenis; J Michel; R Rimoldi; P Lévy; L Israël
Journal:  Eur J Cancer       Date:  1972-10       Impact factor: 9.162

5.  [Selective tumour chemotherapy using oncobiograms (author's transl)].

Authors:  M Volm; M Kaufmann; K Wayss; K Goerttler; J Mattern
Journal:  Dtsch Med Wochenschr       Date:  1974-01-11       Impact factor: 0.628

Review 6.  Monochemotherapy of bronchogenic carcinoma withs special reference to cell type.

Authors:  O S Selawry
Journal:  Cancer Chemother Rep 3       Date:  1973-03

7.  Phase II evaluation of adriamycin in human neoplasia.

Authors:  R M O'Bryan; J K Luce; R W Talley; J A Gottlieb; L H Baker; G Bonadonna
Journal:  Cancer       Date:  1973-07       Impact factor: 6.860

8.  Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.

Authors:  J A Gottlieb; S E Rivkin; S C Spigel; B Hoogstraten; R M O'Bryan; F C Delaney; A Singhakowinta
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

9.  A quick reference chart on cross resistance between anticancer patients.

Authors:  H E Skipper; D J Hutchison; F M Schabel; L H Schmidt; A Goldin; R W Brockman; J M Venditti; I Wodinsky
Journal:  Cancer Chemother Rep       Date:  1972-08

10.  [The use of cell cultures for the determination of the sensitivity of human tumors to cytostatic agents].

Authors:  S Tanneberger; G Bacigalupo
Journal:  Dtsch Gesundheitsw       Date:  1967-01-05
View more
  4 in total

1.  Detection of induced tumour-resistance to cyclophosphamide by the in vitro short term test.

Authors:  M Volm; J Mattern; K Wayss
Journal:  Arch Gynakol       Date:  1977-11-29

2.  Clinical correlates of in vitro effect of adriamycin on advanced lung carcinoma.

Authors:  J Mattern; M Kaufmann; K Wayss; M Volm
Journal:  Klin Wochenschr       Date:  1976-07-15

3.  [Resistance testing of cytostatic agents on human tumors (author's transl)].

Authors:  K Possinger; R Hartenstein; H Ehrhart
Journal:  Klin Wochenschr       Date:  1976-04-15

4.  [In vitro and in vivo sensitivity of animal and human melanomas to various chemotherapeutical agents].

Authors:  A Wiskemann; M Schussmann; D Rothmann; O Schneider
Journal:  Arch Dermatol Res       Date:  1978-08-28       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.